Vonoprazan-Based Triple Therapy with Nitazoxanide versus Non-Bismuth Quadruple Therapy for First-Line Eradication of Helicobacter pylori.

Open-Label Randomized Non-Inferiority Trial Comparing Vonoprazan-Based Triple Therapy with Nitazoxanide versus Non-Bismuth Quadruple Therapy for First-Line Helicobacter pylori Eradication.

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

PACTR

Registry ID

PACTR202605705734927

Enrollment

Registered

2026-05-21

Start date

2026-02-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive System Helicobacter pylori

Interventions

VonoprazanAmoxicillinNitazoxanide

Qudraple

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients above 18 years Confirmed Helicobacter pylori infection by stool antigen (Ag) test or histopathologic examination of gastric samples obtained through upper gastrointestinal tract endoscopy

Exclusion criteria

Exclusion criteria: Patients aged <18 years Those with major chronic disease, such as liver cirrhosis, renal impairment Those with history of previous gastric or duodenal surgery or GIT malignancy Those who had previously received H. pylori treatment Those who received (antacids, proton pump inhibitors (PPIs), H2 receptor antagonists, anticoagulants, or antibiotics) within 6 weeks before study enrollment Those with an allergy to any of the study medications

Design outcomes

Primary

Measure	Time frame
Helicobacter pylori eradication rate	—

Secondary

Measure	Time frame
Safety and tolerability (adverse events incidence and severity);Patient compliance	—

Countries

Egypt

Contacts

Public ContactMarwa ElEmam

Alexandria University

marwadeif0@gmail.com002034862506

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026